For the second quarter of 2026, analysts expect Korro Bio to report a consensus revenue of $0.51 million and an EPS loss of $1.54, with the stock currently trading at $13.25 against an average analyst target of $19.80. Investors are primarily focused on the clinical trajectory for KRRO-121, the company's lead RNA-editing candidate for hyperammonemia, which is slated to enter first-in-human trials in the second half of 2026.
Following the recent discontinuation of its previous lead program for Alpha-1 Antitrypsin Deficiency, the market is closely evaluating the progress of its next-generation candidate, KRRO-111. Management is expected to emphasize its cash runway, which is currently projected to support operations and clinical milestones through late 2028.